Published in J Cell Physiol on November 01, 2011
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
Targeting Mnks for cancer therapy. Oncotarget (2012) 1.96
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res (2013) 1.84
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance. Antioxid Redox Signal (2012) 1.36
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Mechanism-based cancer therapy: resistance to therapy, therapy for resistance. Oncogene (2014) 1.10
Emerging targeted therapies for melanoma treatment (review). Int J Oncol (2014) 1.10
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells. Front Oncol (2013) 1.10
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr Med Chem (2012) 1.02
The APC/C Ubiquitin Ligase: From Cell Biology to Tumorigenesis. Front Oncol (2012) 1.01
Targeting Apoptosis and Multiple Signaling Pathways with Icariside II in Cancer Cells. Int J Biol Sci (2015) 0.92
Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells. Oncotarget (2011) 0.89
VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Mol Cancer Ther (2012) 0.86
The Toll-like receptor 9 ligand, CpG oligodeoxynucleotide, attenuates cardiac dysfunction in polymicrobial sepsis, involving activation of both phosphoinositide 3 kinase/Akt and extracellular-signal-related kinase signaling. J Infect Dis (2013) 0.86
Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res (2015) 0.85
Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review). Int J Oncol (2014) 0.85
Pharmacologically blocking p53-dependent apoptosis protects intestinal stem cells and mice from radiation. Sci Rep (2015) 0.85
Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein. PLoS One (2014) 0.84
Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep (2013) 0.83
Extract of Pleurotus pulmonarius suppresses liver cancer development and progression through inhibition of VEGF-induced PI3K/AKT signaling pathway. PLoS One (2012) 0.83
Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway. Oncotarget (2015) 0.83
Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle (2012) 0.83
Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. Oncol Lett (2015) 0.82
Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells. Mol Cancer (2014) 0.81
Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis (2014) 0.80
Drugging the unfolded protein response in acute leukemias. J Hematol Oncol (2015) 0.79
Isobavachalcone induces the apoptosis of gastric cancer cells via inhibition of the Akt and Erk pathways. Exp Ther Med (2015) 0.79
The role of insulin-like growth factor-I in the physiopathology of hearing. Front Mol Neurosci (2011) 0.79
Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities. Immunotargets Ther (2013) 0.79
Coordination between p21 and DDB2 in the cellular response to UV radiation. PLoS One (2013) 0.78
BRAFV600E-dependent Mcl-1 stabilization leads to everolimus resistance in colon cancer cells. Oncotarget (2016) 0.78
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways. Oncotarget (2016) 0.78
KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. Per Med (2013) 0.77
Reversal of multidrug resistance in MCF-7/Adr cells by codelivery of doxorubicin and BCL2 siRNA using a folic acid-conjugated polyethylenimine hydroxypropyl-β-cyclodextrin nanocarrier. Int J Nanomedicine (2015) 0.77
Detection of rapalog-mediated therapeutic response in renal cancer xenografts using ⁶⁴Cu-bevacizumab immunoPET. PLoS One (2013) 0.77
Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine. Mol Oncol (2017) 0.77
miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. Sci Rep (2016) 0.76
Novel non-AR therapeutic targets in castrate resistant prostate cancer. Transl Androl Urol (2013) 0.75
Detection of Mutant RAS Subpopulations in Colorectal Cancer Patients. EBioMedicine (2015) 0.75
The MST/Hippo Pathway and Cell Death: A Non-Canonical Affair. Genes (Basel) (2016) 0.75
Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation. Mol Syst Biol (2017) 0.75
MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. Biomed Res Int (2017) 0.75
Co-targeting translation and proteasome rapidly kills colon cancer cells with mutant RAS/RAF via ER stress. Oncotarget (2016) 0.75
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul (2006) 3.32
Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep (2008) 2.90
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology (2008) 2.28
Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci U S A (2005) 2.13
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem (2005) 2.11
Metabotropic glutamate receptor-4 modulates adaptive immunity and restrains neuroinflammation. Nat Med (2010) 2.10
Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci (2002) 2.10
PAP/HIP protein is an obesogenic factor. J Cell Physiol (2014) 1.98
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
L-acetylcarnitine causes rapid antidepressant effects through the epigenetic induction of mGlu2 receptors. Proc Natl Acad Sci U S A (2013) 1.94
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol (2003) 1.91
Beta-amyloid monomers are neuroprotective. J Neurosci (2009) 1.87
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci (2004) 1.66
Amplified centrosomes in breast cancer: a potential indicator of tumor aggressiveness. Breast Cancer Res Treat (2002) 1.58
Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci (2005) 1.57
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. Hepatology (2005) 1.57
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
NK cells and cancer. J Immunol (2007) 1.56
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol (2008) 1.56
Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res (2003) 1.55
Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget (2012) 1.55
PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle (2009) 1.54
Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem (2003) 1.50
Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl) (2009) 1.50
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res (2010) 1.46
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle (2011) 1.46
Vitamin D3: a helpful immuno-modulator. Immunology (2011) 1.46
Functional characterization of WNT7A signaling in PC12 cells: interaction with A FZD5 x LRP6 receptor complex and modulation by Dickkopf proteins. J Biol Chem (2003) 1.44
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy (Review). Int J Oncol (2003) 1.43
B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle (2004) 1.43